Seminars in Oncology
Volume 35, Issue 6 , Pages 643-651, December 2008

Cancer Therapy and Osteoporosis: Approach to Evaluation and Management

  • G.J. van Londen

      Affiliations

    • Department of Medicine, Divisions of Geriatrics and Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • ,
  • Pamela Taxel

      Affiliations

    • Departments of Medicine, Division of Endocrinology and Metabolism, University of Connecticut Health Center, Farmington, CT
  • ,
  • Catherine Van Poznak

      Affiliations

    • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
    • Corresponding Author InformationAddress correspondence to Catherine Van Poznak, MD, University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Dr, C346 Med Inn Building, Ann Arbor MI 48109

The incidences of osteoporosis and cancer increase with age, and these two diagnoses are often made in the same individual. Both increasing age and hypogonadism associated with aging, as well as cancer therapies, can lead to loss of bone mass and increased risk for fragility fractures. Advancing age carries an association with increased incidence of cancers. Thus, cancer and its therapies may predispose an individual to osteoporosis and its associated morbidity and mortality. Prevention of bone loss and its consequent fractures is critical in the care of aging patients. This article reviews the mechanisms of bone metabolism and the principles of management of bone health in the older population with a history of cancer.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 C.V.P. has served as consultant for Amgen (12/07) and Roche (12/06).

PII: S0093-7754(08)00191-7

doi:10.1053/j.seminoncol.2008.08.008

Seminars in Oncology
Volume 35, Issue 6 , Pages 643-651, December 2008